Vermont Regenerative Medicine

Vermont Regenerative Medicine offers non-surgical regenerative orthopedic treatments using autologous cell-based injectates such as bone marrow concentrate and platelet-rich plasma. These procedures are performed with image guidance and have been shown to reduce pain and improve function in musculoskeletal conditions. The company tracks patient outcomes through an active registry, reporting high rates of improvement for many treated conditions[4].

Clinical success rates for regenerative injection treatments can be as high as ~91% depending on location of injury; patient-reported results show sustained improvements in pain reduction and joint function up to six years post-procedure for some patients[10].

The company does not conduct traditional drug development or clinical trials but participates in ongoing outcome tracking via the broader Regenexx network.

Published research on Regenexx injectates accounts for about half of all global research on bone marrow concentrate use in orthopedics as of early January, 2019[2].

More than ~159,000 image-guided procedures using these methods have been performed across the network since inception.

No specific drugs or investigational new drugs are developed by this entity.

Pipeline breadth/pipeline programs do not apply; see below.